Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 1/2019

21.01.2019 | ORIGINAL ARTICLE

The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis

verfasst von: Hangqi Luo, Changzuan Zhou, Jufang Chi, Sunlei Pan, Hui Lin, Feidan Gao, Tingjuan Ni, Liping Meng, Jie Zhang, Chengjian Jiang, Zheng Ji, Haitao Lv, Hangyuan Guo

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The role of endoplasmic reticulum (ER) stress in cardiovascular disease is now recognized. Tauroursodeoxycholic acid (TUDCA) is known to have cardiovascular protective effects by decreasing ER stress. This study aimed to assess the ability of TUDCA to decrease ER stress, inhibit dedifferentiation of vascular smooth muscle cells (VSMCs), and reduce in-stent restenosis.

Methods

The effect of TUDCA on dedifferentiation of VSMCs and ER stress was investigated in vitro using wound-healing assays, MTT assays, and western blotting. For in vivo studies, 18 rabbits were fed an atherogenic diet to induce atheroma formation. Bare metal stents (BMS), BMS+TUDCA or Firebird stents were implanted in the left common carotid artery. Rabbits were euthanized after 28 days and processed for scanning electron microscope (SEM), histological examination (HE), and immunohistochemistry.

Results

In vitro TUDCA (10–1000 μmol/L) treatment significantly inhibited platelet-derived growth factor (PDGF)-BB-induced proliferation and migration in VSMCs in a concentration-dependent manner and decreased ER stress markers (IRE1, XBP1, KLF4, and GRP78). In vivo, we confirmed no significant difference in neointimal coverage on three stents surfaces; neointimal was significantly lower with BMS+TUDCA (1.6 ± 0.2 mm2) compared with Firebird (1.90 ± 0.1 mm2) and BMS (2.3 ± 0.1 mm2). Percent stenosis was lowest for BMS+TUDCA, then Firebird, and was significantly higher with BMS (28 ± 4%, 35 ± 7%, 40 ± 1%; respectively; P < 0.001). TUDCA treatment decreased ER stress in the BMS+TUDCA group compared with BMS.

Conclusions

TUDCA inhibited dedifferentiation of VSMCs by decreasing ER stress and reduced in-stent restenosis, possibly through downregulation of the IRE1/XBP1 signaling pathway.
Literatur
1.
Zurück zum Zitat Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.CrossRefPubMed Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.CrossRefPubMed
2.
Zurück zum Zitat Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496–507.CrossRefPubMed Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496–507.CrossRefPubMed
3.
Zurück zum Zitat Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 2009;73:615–21.CrossRefPubMed Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 2009;73:615–21.CrossRefPubMed
4.
Zurück zum Zitat Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand RK, Patel TM, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. N Engl J Med. 2015;373:1709–19.CrossRefPubMed Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand RK, Patel TM, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. N Engl J Med. 2015;373:1709–19.CrossRefPubMed
5.
Zurück zum Zitat de la Torre Hernandez JM, Alfonso F, Martin Yuste V, Sanchez Recalde A, Jimenez Navarro MF, Perez de Prado A, et al. Comparison of paclitaxel and everolimus-eluting stents in st-segment elevation myocardial infarction and influence of thrombectomy on outcomes. Estrofa-im study. Rev Esp Cardiol (Engl Ed). 2014;67:999–1006.CrossRef de la Torre Hernandez JM, Alfonso F, Martin Yuste V, Sanchez Recalde A, Jimenez Navarro MF, Perez de Prado A, et al. Comparison of paclitaxel and everolimus-eluting stents in st-segment elevation myocardial infarction and influence of thrombectomy on outcomes. Estrofa-im study. Rev Esp Cardiol (Engl Ed). 2014;67:999–1006.CrossRef
6.
Zurück zum Zitat Pan M, Burzotta F, Trani C, Medina A, Suarez de Lezo J, Niccoli G, et al. Three-year follow-up of patients with bifurcation lesions treated with sirolimus- or everolimus-eluting stents: seaside and corpal cooperative study. Rev Esp Cardiol (Engl Ed). 2014;67:797–803.CrossRef Pan M, Burzotta F, Trani C, Medina A, Suarez de Lezo J, Niccoli G, et al. Three-year follow-up of patients with bifurcation lesions treated with sirolimus- or everolimus-eluting stents: seaside and corpal cooperative study. Rev Esp Cardiol (Engl Ed). 2014;67:797–803.CrossRef
7.
Zurück zum Zitat Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333–42.CrossRefPubMed Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333–42.CrossRefPubMed
8.
Zurück zum Zitat Zhang DP, Ge YG, Ni ZH. Very late angiographic stent thrombosis after sirolimus-eluting stent implantation at 54 months. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36:176–7.PubMed Zhang DP, Ge YG, Ni ZH. Very late angiographic stent thrombosis after sirolimus-eluting stent implantation at 54 months. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36:176–7.PubMed
9.
Zurück zum Zitat Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J. 2007;71:226–8.CrossRefPubMed Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J. 2007;71:226–8.CrossRefPubMed
10.
Zurück zum Zitat Kuriyama N, Kobayashi Y, Nakama T, Mine D, Nishihira K, Shimomura M, et al. Late restenosis following sirolimus-eluting stent implantation. JACC Cardiovasc Interv. 2011;4:123–8.CrossRefPubMed Kuriyama N, Kobayashi Y, Nakama T, Mine D, Nishihira K, Shimomura M, et al. Late restenosis following sirolimus-eluting stent implantation. JACC Cardiovasc Interv. 2011;4:123–8.CrossRefPubMed
11.
Zurück zum Zitat Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-cypher registry. Circulation. 2012;125:584–91.CrossRefPubMed Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-cypher registry. Circulation. 2012;125:584–91.CrossRefPubMed
12.
Zurück zum Zitat Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2051–7.CrossRefPubMed Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2051–7.CrossRefPubMed
13.
Zurück zum Zitat Shah R, Ramos-Bondy B, Mizeracki A. Risk of stent thrombosis with bioresorbable vascular scaffolds. Lancet. 2016;387:1903.CrossRefPubMed Shah R, Ramos-Bondy B, Mizeracki A. Risk of stent thrombosis with bioresorbable vascular scaffolds. Lancet. 2016;387:1903.CrossRefPubMed
14.
Zurück zum Zitat Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The udca-pbc study group. N Engl J Med. 1994;330:1342–7.CrossRefPubMed Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The udca-pbc study group. N Engl J Med. 1994;330:1342–7.CrossRefPubMed
15.
Zurück zum Zitat Rudolph G, Endele R, Senn M, Stiehl A. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology. 1993;17:1028–32.CrossRefPubMed Rudolph G, Endele R, Senn M, Stiehl A. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology. 1993;17:1028–32.CrossRefPubMed
16.
Zurück zum Zitat Luketic VA, Sanyal AJ. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease. Gastroenterologist. 1994;2:74–9.PubMed Luketic VA, Sanyal AJ. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease. Gastroenterologist. 1994;2:74–9.PubMed
17.
Zurück zum Zitat Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J, et al. New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of mmp-9. Arterioscler Thromb Vasc Biol. 2009;29:472–9.CrossRefPubMed Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J, et al. New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of mmp-9. Arterioscler Thromb Vasc Biol. 2009;29:472–9.CrossRefPubMed
18.
Zurück zum Zitat Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol. 1998;13:659–64.CrossRefPubMed Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol. 1998;13:659–64.CrossRefPubMed
19.
Zurück zum Zitat Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3:58–69.CrossRefPubMedPubMedCentral Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3:58–69.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Cho JG, Lee JH, Hong SH, Lee HN, Kim CM, Kim SY, et al. Tauroursodeoxycholic acid, a bile acid, promotes blood vessel repair by recruiting vasculogenic progenitor cells. Stem Cells. 2015;33:792–805.CrossRefPubMed Cho JG, Lee JH, Hong SH, Lee HN, Kim CM, Kim SY, et al. Tauroursodeoxycholic acid, a bile acid, promotes blood vessel repair by recruiting vasculogenic progenitor cells. Stem Cells. 2015;33:792–805.CrossRefPubMed
21.
Zurück zum Zitat Ma J, Nakajima T, Iida H, Iwasawa K, Terasawa K, Oonuma H, et al. Inhibitory effects of ursodeoxycholic acid on the induction of nitric oxide synthase in vascular smooth muscle cells. Eur J Pharmacol. 2003;464:79–86.CrossRefPubMed Ma J, Nakajima T, Iida H, Iwasawa K, Terasawa K, Oonuma H, et al. Inhibitory effects of ursodeoxycholic acid on the induction of nitric oxide synthase in vascular smooth muscle cells. Eur J Pharmacol. 2003;464:79–86.CrossRefPubMed
22.
Zurück zum Zitat Lee WY, Han SH, Cho TS, Yoo YH, Lee SM. Effect of ursodeoxycholic acid on ischemia/reperfusion injury in isolated rat heart. Arch Pharm Res. 1999;22:479–84.CrossRefPubMed Lee WY, Han SH, Cho TS, Yoo YH, Lee SM. Effect of ursodeoxycholic acid on ischemia/reperfusion injury in isolated rat heart. Arch Pharm Res. 1999;22:479–84.CrossRefPubMed
23.
Zurück zum Zitat Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (tudca) inhibits neointimal hyperplasia by suppression of erk via pkcalpha-mediated mkp-1 induction. Cardiovasc Res. 2011;92:307–16.CrossRefPubMed Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (tudca) inhibits neointimal hyperplasia by suppression of erk via pkcalpha-mediated mkp-1 induction. Cardiovasc Res. 2011;92:307–16.CrossRefPubMed
24.
Zurück zum Zitat Fan L, Chen LL, Lin CG, Peng YF, Zheng XC, Luo YK, et al. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions. Chin Med J. 2008;121:1518–23.CrossRefPubMed Fan L, Chen LL, Lin CG, Peng YF, Zheng XC, Luo YK, et al. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions. Chin Med J. 2008;121:1518–23.CrossRefPubMed
25.
Zurück zum Zitat Gao Z, Yang YJ, Chen JL, Qiao SB, Xu B, Qin XW, et al. Effects of sirolimus-eluting stent and the paclitaxel-eluting stent: a three-year follow-up study. Zhonghua Yi Xue Za Zhi. 2008;88:1811–4.PubMed Gao Z, Yang YJ, Chen JL, Qiao SB, Xu B, Qin XW, et al. Effects of sirolimus-eluting stent and the paclitaxel-eluting stent: a three-year follow-up study. Zhonghua Yi Xue Za Zhi. 2008;88:1811–4.PubMed
26.
Zurück zum Zitat Gao H, Yan HB, Zhu XL, Li N, Ai H, Wang J, et al. Firebird sirolimus eluting stent versus bare mental stent in patients with st-segment elevation myocardial infarction. Chin Med J. 2007;120:863–7.CrossRefPubMed Gao H, Yan HB, Zhu XL, Li N, Ai H, Wang J, et al. Firebird sirolimus eluting stent versus bare mental stent in patients with st-segment elevation myocardial infarction. Chin Med J. 2007;120:863–7.CrossRefPubMed
27.
Zurück zum Zitat Iaconetti C, De Rosa S, Polimeni A, Sorrentino S, Gareri C, Carino A, et al. Down-regulation of mir-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res. 2015;107:522–33.CrossRefPubMed Iaconetti C, De Rosa S, Polimeni A, Sorrentino S, Gareri C, Carino A, et al. Down-regulation of mir-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res. 2015;107:522–33.CrossRefPubMed
28.
Zurück zum Zitat Fitzgerald TN, Shepherd BR, Asada H, Teso D, Muto A, Fancher T, et al. Laminar shear stress stimulates vascular smooth muscle cell apoptosis via the akt pathway. J Cell Physiol. 2008;216:389–95.CrossRefPubMed Fitzgerald TN, Shepherd BR, Asada H, Teso D, Muto A, Fancher T, et al. Laminar shear stress stimulates vascular smooth muscle cell apoptosis via the akt pathway. J Cell Physiol. 2008;216:389–95.CrossRefPubMed
29.
Zurück zum Zitat Palumbo R, Gaetano C, Melillo G, Toschi E, Remuzzi A, Capogrossi MC. Shear stress downregulation of platelet-derived growth factor receptor-beta and matrix metalloprotease-2 is associated with inhibition of smooth muscle cell invasion and migration. Circulation. 2000;102:225–30.CrossRefPubMed Palumbo R, Gaetano C, Melillo G, Toschi E, Remuzzi A, Capogrossi MC. Shear stress downregulation of platelet-derived growth factor receptor-beta and matrix metalloprotease-2 is associated with inhibition of smooth muscle cell invasion and migration. Circulation. 2000;102:225–30.CrossRefPubMed
30.
Zurück zum Zitat Garanich JS, Pahakis M, Tarbell JM. Shear stress inhibits smooth muscle cell migration via nitric oxide-mediated downregulation of matrix metalloproteinase-2 activity. Am J Physiol Heart Circ Physiol. 2005;288:H2244–52.CrossRefPubMed Garanich JS, Pahakis M, Tarbell JM. Shear stress inhibits smooth muscle cell migration via nitric oxide-mediated downregulation of matrix metalloproteinase-2 activity. Am J Physiol Heart Circ Physiol. 2005;288:H2244–52.CrossRefPubMed
31.
Zurück zum Zitat Wang CF, Yuan JR, Qin D, Gu JF, Zhao BJ, Zhang L, et al. Protection of tauroursodeoxycholic acid on high glucose-induced human retinal microvascular endothelial cells dysfunction and streptozotocin-induced diabetic retinopathy rats. J Ethnopharmacol. 2016;185:162–70.CrossRefPubMed Wang CF, Yuan JR, Qin D, Gu JF, Zhao BJ, Zhang L, et al. Protection of tauroursodeoxycholic acid on high glucose-induced human retinal microvascular endothelial cells dysfunction and streptozotocin-induced diabetic retinopathy rats. J Ethnopharmacol. 2016;185:162–70.CrossRefPubMed
32.
Zurück zum Zitat Chen S, Liu B, Kong D, Li S, Li C, Wang H, et al. Atorvastatin calcium inhibits phenotypic modulation of pdgf-bb-induced vsmcs via down-regulation the akt signaling pathway. PLoS One. 2015;10:e0122577.CrossRefPubMedPubMedCentral Chen S, Liu B, Kong D, Li S, Li C, Wang H, et al. Atorvastatin calcium inhibits phenotypic modulation of pdgf-bb-induced vsmcs via down-regulation the akt signaling pathway. PLoS One. 2015;10:e0122577.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res. 2008;38:123–31.PubMed Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res. 2008;38:123–31.PubMed
34.
Zurück zum Zitat Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:318–28.CrossRefPubMed Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:318–28.CrossRefPubMed
35.
Zurück zum Zitat Hua Y, Kandadi MR, Zhu M, Ren J, Sreejayan N. Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages. J Cardiovasc Pharmacol. 2010;55:49–55.CrossRefPubMedPubMedCentral Hua Y, Kandadi MR, Zhu M, Ren J, Sreejayan N. Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages. J Cardiovasc Pharmacol. 2010;55:49–55.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce er stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137–40.CrossRefPubMedPubMedCentral Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce er stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137–40.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Chen Y, Liu CP, Xu KF, Mao XD, Lu YB, Fang L, et al. Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced glycation end products in cultured mouse podocytes. Am J Nephrol. 2008;28:1014–22.CrossRefPubMed Chen Y, Liu CP, Xu KF, Mao XD, Lu YB, Fang L, et al. Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced glycation end products in cultured mouse podocytes. Am J Nephrol. 2008;28:1014–22.CrossRefPubMed
38.
Zurück zum Zitat Yanagitani K, Imagawa Y, Iwawaki T, Hosoda A, Saito M, Kimata Y, et al. Cotranslational targeting of xbp1 protein to the membrane promotes cytoplasmic splicing of its own mrna. Mol Cell. 2009;34:191–200.CrossRefPubMed Yanagitani K, Imagawa Y, Iwawaki T, Hosoda A, Saito M, Kimata Y, et al. Cotranslational targeting of xbp1 protein to the membrane promotes cytoplasmic splicing of its own mrna. Mol Cell. 2009;34:191–200.CrossRefPubMed
39.
Zurück zum Zitat Zeng L, Li Y, Yang J, Wang G, Margariti A, Xiao Q, et al. Xbp 1-deficiency abrogates neointimal lesion of injured vessels via cross talk with the pdgf signaling. Arterioscler Thromb Vasc Biol. 2015;35:2134–44.CrossRefPubMed Zeng L, Li Y, Yang J, Wang G, Margariti A, Xiao Q, et al. Xbp 1-deficiency abrogates neointimal lesion of injured vessels via cross talk with the pdgf signaling. Arterioscler Thromb Vasc Biol. 2015;35:2134–44.CrossRefPubMed
40.
Zurück zum Zitat Ben Mosbah I, Alfany-Fernandez I, Martel C, Zaouali MA, Bintanel-Morcillo M, Rimola A, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis. 2010;1:e52.CrossRefPubMed Ben Mosbah I, Alfany-Fernandez I, Martel C, Zaouali MA, Bintanel-Morcillo M, Rimola A, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis. 2010;1:e52.CrossRefPubMed
41.
Zurück zum Zitat Omar HR, Sprenker C, Karlnoski R, Camporesi EM, Mangar D. Late and very late drug-eluting stent thrombosis in the immediate postoperative period after antiplatelet withdrawal: a retrospective study. Ther Adv Cardiovasc Dis. 2014;8:185–92.CrossRefPubMed Omar HR, Sprenker C, Karlnoski R, Camporesi EM, Mangar D. Late and very late drug-eluting stent thrombosis in the immediate postoperative period after antiplatelet withdrawal: a retrospective study. Ther Adv Cardiovasc Dis. 2014;8:185–92.CrossRefPubMed
42.
Zurück zum Zitat Franck C, Eisenberg MJ, Dourian T, Grandi SM, Filion KB. Very late stent thrombosis in patients with first-generation drug-eluting stents: a systematic review of reported cases. Int J Cardiol. 2014;177:1056–8.CrossRefPubMed Franck C, Eisenberg MJ, Dourian T, Grandi SM, Filion KB. Very late stent thrombosis in patients with first-generation drug-eluting stents: a systematic review of reported cases. Int J Cardiol. 2014;177:1056–8.CrossRefPubMed
43.
Zurück zum Zitat Bechiri MY, Souteyrand G, Lefevre T, Trouillet C, Range G, Cayla G, et al. Characteristics of stent thrombosis in bifurcation lesions analysed by optical coherence tomography [J]. EuroIntervention. 2018;13(18):e2174–e2181. Bechiri MY, Souteyrand G, Lefevre T, Trouillet C, Range G, Cayla G, et al. Characteristics of stent thrombosis in bifurcation lesions analysed by optical coherence tomography [J]. EuroIntervention. 2018;13(18):e2174–e2181.
Metadaten
Titel
The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis
verfasst von
Hangqi Luo
Changzuan Zhou
Jufang Chi
Sunlei Pan
Hui Lin
Feidan Gao
Tingjuan Ni
Liping Meng
Jie Zhang
Chengjian Jiang
Zheng Ji
Haitao Lv
Hangyuan Guo
Publikationsdatum
21.01.2019
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 1/2019
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-018-6844-4

Weitere Artikel der Ausgabe 1/2019

Cardiovascular Drugs and Therapy 1/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.